Anavex Life Sciences Corp. (AVXL)
| Market Cap | 845.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -47.98M |
| Shares Out | 77.96M |
| EPS (ttm) | -0.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 239,800 |
| Open | 10.89 |
| Previous Close | 10.87 |
| Day's Range | 10.57 - 10.98 |
| 52-Week Range | 7.13 - 15.24 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 43.35 (+301.39%) |
| Earnings Date | Feb 8, 2023 |
About AVXL
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multip... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for AVXL stock is "Buy." The 12-month stock price forecast is $43.35, which is an increase of 301.39% from the latest price.
News
Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer's Trial
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...
Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...
Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal
Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.
Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
Webcast and Conference Call To be Held Monday December 5, 2022, 8:30 am ET Webcast and Conference Call To be Held Monday December 5, 2022, 8:30 am ET
Why Is Anavex Life Sciences (AVXL) Stock Up 30% Today?
Anavex Life Sciences (NASDAQ: AVXL) stock is rocketing higher on Friday following positive results from a clinical trial. The results come from its Phase 2b/3 clinical trial of ANAVEX®2-73.
ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer's Disease
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...
Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. Eastern Time
Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
Webcast and Conference Call To be Held Monday November 28, 2022, 8:30 am ET Webcast and Conference Call To be Held Monday November 28, 2022, 8:30 am ET
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome
NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...
Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer's Disease at the Upcoming Clinical Trials on Alzheimer's Disease (CTAD) Congress 2022
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...
Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy
Issuance of Anavex's Newest U.S. Patent Will Expand Anavex's Intellectual Property Portfolio Surrounding ANAVEX®2-73 Issuance of Anavex's Newest U.S. Patent Will Expand Anavex's Intellectual Property ...
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease
Mechanism of Action of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) is the activation of SIGMAR1
Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Third Quarter Financial Results
Company to host a webcast today at 4:30 p.m. Eastern Time
Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday August 9, 2022
Webcast and Conference Call To be Held Tuesday August 9, 2022, 4:30 pm ET Webcast and Conference Call To be Held Tuesday August 9, 2022, 4:30 pm ET
Anavex Announces Long-lasting Effect of ANAVEX®3-71 Preventing Cognitive Decline in a Transgenic Rat Model of Alzheimer's Disease at AAIC 2022
ANAVEX®3-71 effect is supported by biomarkers: Decrease of extracellular A (Abeta) deposition and reduced pathological inflammatory glial cell recruitment towards hippocampal neurons (p ≤ 0.01) ANAVEX...
Anavex Announces First Entire Clinical Alzheimer's Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Expression levels of pathological dysregulated neurodegenerative genes of both Alzheimer's and Parkinson's disease were significantly restored by the therapeutic effect of ANAVEX®2-73 (p
Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 179%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 179.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionab...
Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 238%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 238.3% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionab...
How Much Upside is Left in Anavex Life Sciences (AVXL)? Wall Street Analysts Think 286%
The average of price targets set by Wall Street analysts indicates a potential upside of 286.4% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionab...
Anavex's Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome
Publication Demonstrates the Feasibility to Use Blood Biomarkers to Monitor Response to ANAVEX®2-73 (blarcamesine) in Clinical Trials of Fragile X Syndrome (Major Cause of Autism) Publication Demonstr...
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 265% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 265% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable...
Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results
Company to host a webcast today at 4:30 p.m. Eastern Time
(AVXL) News: Did You Lose Money on Anavex Life Sciences Corp. Investment? Contact Johnson Fistel Regarding Class Action Investigation
San Diego, California--(Newsfile Corp. - May 6, 2022) - Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of federal securities laws by Anavex Life Sciences Corp. (...